Want to see OKYO full AI Analyst Report?

OKYO Pharma Limited Sponsored ADR (OKYO) Price & Analysis

123 Followers

OKYO Stock Chart & Stats

$1.66

$0.09(7.75%)

At close: Jan 08 4:00 PM EST

$1.66

$0.09(7.75%)

Day’s Range― - ―

52-Week Range$1.34 - $3.35

Previous CloseN/A

Volume700.83K

Average Volume (3M)131.52K

Market Cap

$88.17M

Enterprise Value$56.20M

Total Cash (Recent Filing)$20.59M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.51

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding52,479,527

10 Day Avg. Volume47,624

30 Day Avg. Volume131,524

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)4.88

Price to Sales (P/S)0.00

P/FCF Ratio-10.12

Enterprise Value/Market Cap0.64

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-30.88K

Enterprise Value/Ebitda-8.77

Forecast

1Y Price Target

$5.00

Price Target Upside201.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development Progress And Market PotentialA planned 120-patient Phase 2b/3 multiple-dose trial, combined with no currently approved therapies for this condition and a differentiated mechanism, creates a clear clinical catalyst and sizable commercial opportunity if efficacy is confirmed.

Clinical Efficacy And SafetyPhase 2 results demonstrated meaningful pain reduction with urcosimod while maintaining a clean safety profile, supporting potential clinical benefit for patients with neuropathic corneal pain.

Regulatory AlignmentFDA endorsement of the pain scale as a clinically meaningful endpoint, together with agreement on study design, sample size and statistical guidance, increases the chance of a robust pivotal trial and clearer regulatory pathway.

Bears Say

Limited Data On Corneal Nerve FindingsCorneal image improvements are derived from a small exploratory analysis and require confirmation in larger trials, leaving the nerve restoration signal uncertain.

Program Risk ProfileThe program faces risks across clinical, regulatory, commercial, financing and intellectual property areas, any of which could delay development or limit future market access.

OKYO Pharma Limited Sponsored ADR News

Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49

Okyo Pharma (OKYO) announced that Raj Patil, chief scientific officer of Okyo Pharma has increased his holdings with...

6d ago

OKYO

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

OKYO Pharma (OKYO)announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares...

11d ago

OKYO

Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54

Okyo Pharma (OKYO) announced that Okyo Pharma’s CEO, Robert Dempsey, has purchased 15,000 of the company’s ordinary shares...

11d ago

OKYO

Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share

OKYO Pharma (OKYO) announced that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he...

12d ago

OKYO

Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share

OKYO Pharma (OKYO) Limited announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma...

12d ago

OKYO

Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40

Okyo Pharma (OKYO) announced that Okyo Pharma’s CMO, Flavio Mantelli, has purchased 20,000 of the company’s ordinary shares...

12d ago

OKYO

Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share

Okyo Pharma (OKYO) announced that its chairman, Gabriele Cerrone, through Panetta Partners, an entity in which he has...

13d ago

OKYO

Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Okyo Pharma (OKYO) to $5 from $7 and keeps a...

21d ago

OKYO

Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway

Okyo Pharma (OKYO) announced feedback from its FDA Type D meeting, validating the company’s regulatory and clinical path...

26d ago

OKYO

OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial

An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. OKYO Pharma reported on...

6d ago

OKYO

OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. OKYO Pharma Limited is a clinical-stage...

7d ago

OKYO

OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On July 23, 2026, OKYO Pharma...

11d ago

OKYO

OKYO Pharma CEO Boosts Stake With Nasdaq Share Purchase

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has issued an update. On July 23, 2026, OKYO Pharma...

11d ago

OKYO

OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an update. On July 22, 2026, OKYO Pharma...

12d ago

OKYO

OKYO FAQ

What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?

OKYO Pharma Limited Sponsored ADR lowest stock price was $1.34 and its highest was $3.35 in the past 12 months.

What is OKYO Pharma Limited Sponsored ADR’s market cap?

OKYO Pharma Limited Sponsored ADR’s market cap is $88.17M.

When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?

Currently, no data Available

Is OKYO Pharma Limited Sponsored ADR overvalued?

According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OKYO Pharma Limited Sponsored ADR pay dividends?

OKYO Pharma Limited Sponsored ADR does not currently pay dividends.

What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?

OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?

OKYO Pharma Limited Sponsored ADR has 52,479,527 shares outstanding.

What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OKYO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

OKYO Pharma Limited Sponsored ADR Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

470.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

OKYO Pharma Limited Sponsored ADR (OKYO) Earnings & Revenues

Historic Earnings Reports

OKYO Stock 12 Month Forecast

Average Price Target

$5.00

▲(201.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,1.9353846153846153,2.190769230769231,2.4461538461538463,2.701538461538462,2.9569230769230774,3.2123076923076925,3.4676923076923076,3.723076923076923,3.9784615384615387,4.233846153846154,4.48923076923077,4.744615384615385,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,1.9353846153846153,2.190769230769231,2.4461538461538463,2.701538461538462,2.9569230769230774,3.2123076923076925,3.4676923076923076,3.723076923076923,3.9784615384615387,4.233846153846154,4.48923076923077,4.744615384615385,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.68,1.9353846153846153,2.190769230769231,2.4461538461538463,2.701538461538462,2.9569230769230774,3.2123076923076925,3.4676923076923076,3.723076923076923,3.9784615384615387,4.233846153846154,4.48923076923077,4.744615384615385,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >